Clinical trial Recruiting at 6 sites Interventional Ages 22 to 70

Evaluating the PerQdisc device for treating low back pain

Official title: A Multi-center Traditional Feasibility Trial of the PerQdisc Artificial Implant in Treatment of Single-level Discogenic Back Pain.

Run by Spinal Stabilization Technologies · NCT06860867 · Data updated 2026-11-12

This study is testing a new device called PerQdisc to see if it can help people with low back pain from degenerative disc disease after other treatments haven’t worked for at least six months.

Quick facts

Study typeInterventional
Ages22 Years to 70 Years
SexAll
Enrollment5 (estimated)
SponsorSpinal Stabilization Technologies
Industry-sponsored
Locations9 sites (Glendale, Arizona and 8 other locations)
StatusRecruiting
StartedJanuary 10, 2025
Main results expectedSeptember 30, 2027
Study endsMarch 31, 2030
Registry record updatedNovember 9, 2026
Trial IDNCT06860867 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 22-70 with single level discogenic low back pain who have not responded to conservative treatments.

Probably not a fit

Patients with multiple levels of disc degeneration or those who have not undergone conservative treatment for at least 6 months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This feasibility study aims to assess the safety and effectiveness of the PerQdisc device in treating single level discogenic low back pain caused by degenerative disc disease. The study will enroll a minimum of 5 participants across 2 sites, who will receive the PerQdisc treatment after failing conservative therapies for at least 6 months. Participants will be monitored for safety and effectiveness, with data collected to support future pivotal trials. The study is open-label, meaning participants will know the treatment they are receiving.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients suffering from chronic low back pain due to degenerative disc disease.

How similar studies have gone: While this approach is being evaluated for the first time in this specific context, similar interventions have shown promise in treating discogenic pain.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Skeletally mature male or female subjects aged 22-70 (inclusive).
2. Subject has a primary diagnosis of single level discogenic back pain caused by degenerative disc disease (L1 to L5) identified via MRI.
3. Subject has an intact annulus (as determined by MRI) and endplates (as determined by MRI and X-ray) at the level to be treated.
4. Subject must have failed to respond to a minimum of 6 months of conservative treatment for their back pain (e.g., physical therapy, medications, injections, ablations, lifestyle changes, etc.).
5. Subject has a low back pain VAS ≥40 mm (4 cm).
6. Subject has adequate disc height (≥6mm measured at the center of the disc) at the level to be treated. \[As measured by the investigator\]
7. Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
8. Subject has read and understands the IRB approved informed consent document prior to signing and dating the document and before the initiation of any study-related procedures
9. Subject is appropriate candidate for the PerQdisc surgical approach \[as defined in the surgical technique guide\].

Exclusion Criteria:

1. Subject has symptomatic degenerative disc disease at more than one lumbar level
2. Subject has had a prior spinal fusion in the lumbar or thoracic intervertebral spaces.
3. Subject has had a prior SI-joint fusion.
4. Subject has a spinal cord stimulator.
5. Subject has had any prior lumbar spine surgery (instrumented or non-instrumented)
6. Subject has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
7. Subject has congenital moderate or severe spinal stenosis or epidural lipomatosis.
8. Subject has spondylolisthesis (antero- or retrolisthesis) in static X-ray ≥3 mm \[measured via neutral lateral x-ray\]
9. Subject has ≥4 mm dynamic spondylolisthesis \[measured via flexion/extension x-rays\]
10. Subject has \> 20 degree range of motion at the index level \[measured via flexion/extension x-rays\]
11. Subject has a history of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).
12. Subject has an active systemic infection or infection at the operative site.
13. Subject has evidence of symptomatic facet joint degeneration or disease where the investigator feels the facet is a major contributor to the subject's pain as diagnosed by injection and/or imaging.
14. Subject has a known allergy to silicone or barium sulfate.
15. Subject has been diagnosed with fibromyalgia, hepatitis, rheumatoid arthritis, lupus erythematosus, AIDs, ARC, HIV, or an autoimmune disease that affects the musculoskeletal system.
16. Subject has been diagnosed with Paget's disease, osteomalacia or any other metabolic bone disease.
17. Subject has current or recent history (defined ≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) using standard medical definitions of DSM-5
18. Subject has morbid obesity defined as a body mass index (BMI) \> 40.
19. Subject participated in an investigational drug or another medical device study within the last 30 days prior to surgery.
20. Subject has Osteoporosis, defined as a T-score ≤ -2.5.

    1. An existing DEXA is allowed if completed within 6 months of subject surgery.
    2. For all subjects without an existing DEXA, the SCORE/MORES will be utilized to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required.
21. Female subjects who are pregnant or are trying to become pregnant during the course of the trial.
22. Subject has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
23. Subject belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)
24. Subject is currently receiving worker's compensation or is involved in any litigation for medical negligence, trauma, or worker's compensation.
25. Subject has lumbar scoliosis \> 10 degrees at index level.
26. Subject has a large, rectangular or irregularly shaped Schmorl's node with an associated active inflammatory process (Modic I changes).
27. Subject has motion of \< 3 degrees on pre-operative lateral flexion/extension radiographs at index level.
28. Subject has opioid medication usage \> 60 MME (morphine milligram equivalent)/day or change in opioid prescription within 60 days of surgery.
29. Subject has a preoperative VAS right or left leg pain score \> the preoperative VAS Back score.
30. Subject has a history of vertebral fractures in the lumbar spine.
31. Subject has evidence of severe compression of cauda equina.
32. Subject is on chronic anticoagulation therapy due to a bleeding disorder and is unable to safely stop anticoagulants or has taken anticoagulants within 3 days prior to procedure.
33. Subject has low back pain (LBP) of non-spinal or unknown etiology.
34. Subject is unable to undergo X-ray, MRI, or other radiographic assessments, including discography.
35. Subject has a degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to spinal disease (not at index level), Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
36. Subject has, in the opinion of the investigator, a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device.
37. In the opinion of the investigator the subject has a major psychiatric disorder that may interfere with the assessment of the safety or effectiveness of the device.
38. Subject has myelopathy.
39. Subject has primarily leg pain with associated nerve root compression, in the opinion of the investigator.
40. Subject has an annular defect greater than 6mm that extends from the interior of the disc to the outer margin of the annulus as evaluated on MRI.

Where it's running

  • The CORE Institute
    Phoenix, Arizona, United States
    Recruiting
  • HonorHealth Research & Innovation Institute
    Scottsdale, Arizona, United States
    Recruiting
  • University of Miami
    Miami, Florida, United States
    Recruiting
  • Axis Spine Center
    Coeur d'Alene, Idaho, United States
    Recruiting
  • Indiana Spine Group
    Carmel, Indiana, United States
    Recruiting
  • Spine Institute of Louisiana
    Shreveport, Louisiana, United States
    Recruiting
Show 3 more locations
  • Hope Research Institute
    Glendale, Arizona, United States
    Withdrawn
  • HOPE Research Institute
    Phoenix, Arizona, United States
    Withdrawn
  • SonoSpine
    Oklahoma City, Oklahoma, United States
    Withdrawn

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Electroacupuncture for treating discogenic low back pain

    This study is testing if electroacupuncture can help people aged 18 to 70 with disc-related low back pain feel better and improve their daily activities.

    Recruiting Beijing Hospital · Beijing, Beijing Municipality · NCT06703671

  • Minimally invasive artificial disc replacement for chronic low back pain

    This study is testing a new device for replacing damaged discs in the lower back to see if it can help people with chronic back pain feel better without the downsides of traditional surgery.

    Recruiting at 4 sites Spinal Stabilization Technologies · Medellín, Antioquia and 10 other locations · NCT05508360

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.